IgA inhibitor to factor VIII/von Willebrand factor.
A 60-year-old Black female presented with a haemorrhagic diathesis and an acquired factor VIII/von Willebrand factor (VIII/vWf) inhibitor. This inhibitor was classified as an IgA immunoglobulin and was active not only against factor VIII coagulant (VIII:C) activity but also against plasma von Willebrand factor (vWf). The purified IgA also interacted with normal platelets to inhibit ristocetin-induced platelet aggregation (RIPA). In contrast, studies with haemophilia A plasma and platelets revealed that the inhibitor did not react significantly with these plasmas or platelets. The significant differences in the inhibition of vWf assay both of the plasma and the platelets of the haemophilia A patients suggests that part of the haemorrhagic diathesis may be related not only to the inhibition of VIII:C but also to interference with platelet function. In addition, these studies suggest that there may be significant differences in the factor VIII-related antigen (VIII R:Ag) on platelets in haemophilia A patients compared to normal.
D001779:Blood Coagulation Factors / Q000276:immunology*; D001780:Blood Coagulation Tests; D005169:Factor VIII / Q000037:antagonists & inhibitors*; D005260:Female; D006467:Hemophilia A / Q000097:blood; D006474:Hemorrhagic Disorders / Q000097:blood* / Q000276:immunology; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D008875:Middle Aged; D010974:Platelet Aggregation; D012310:Ristocetin / Q000494:pharmacology; D014841:von Willebrand Factor / Q000276:immunology*
D001779:Blood Coagulation Factors; D007070:Immunoglobulin A; D014841:von Willebrand Factor; D012310:Ristocetin; D005169:Factor VIII